BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36749655)

  • 1. DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations.
    Gallon J; Rodriguez-Calero A; Benjak A; Akhoundova D; Maletti S; Amstutz U; Hewer E; Genitsch V; Fleischmann A; Rushing EJ; Grobholz R; Fischer I; Jochum W; Cathomas G; Osunkoya AO; Bubendorf L; Moch H; Thalmann G; Feng FY; Gillessen S; Ng CKY; Rubin MA; Piscuoglio S
    Cancer Res; 2023 Apr; 83(8):1203-1213. PubMed ID: 36749655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.
    Yegnasubramanian S; Haffner MC; Zhang Y; Gurel B; Cornish TC; Wu Z; Irizarry RA; Morgan J; Hicks J; DeWeese TL; Isaacs WB; Bova GS; De Marzo AM; Nelson WG
    Cancer Res; 2008 Nov; 68(21):8954-67. PubMed ID: 18974140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
    Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
    Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.
    Kim JH; Dhanasekaran SM; Prensner JR; Cao X; Robinson D; Kalyana-Sundaram S; Huang C; Shankar S; Jing X; Iyer M; Hu M; Sam L; Grasso C; Maher CA; Palanisamy N; Mehra R; Kominsky HD; Siddiqui J; Yu J; Qin ZS; Chinnaiyan AM
    Genome Res; 2011 Jul; 21(7):1028-41. PubMed ID: 21724842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond the island: epigenetic biomarkers of colorectal and prostate cancer.
    Savio AJ; Bapat B
    Methods Mol Biol; 2015; 1238():103-24. PubMed ID: 25421657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.
    Börno ST; Fischer A; Kerick M; Fälth M; Laible M; Brase JC; Kuner R; Dahl A; Grimm C; Sayanjali B; Isau M; Röhr C; Wunderlich A; Timmermann B; Claus R; Plass C; Graefen M; Simon R; Demichelis F; Rubin MA; Sauter G; Schlomm T; Sültmann H; Lehrach H; Schweiger MR
    Cancer Discov; 2012 Nov; 2(11):1024-35. PubMed ID: 22930729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
    Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
    Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer.
    Yu YP; Ding Y; Chen R; Liao SG; Ren BG; Michalopoulos A; Michalopoulos G; Nelson J; Tseng GC; Luo JH
    Am J Pathol; 2013 Dec; 183(6):1960-1970. PubMed ID: 24113458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in homologous recombination repair genes in prostate cancer brain metastases.
    Rodriguez-Calero A; Gallon J; Akhoundova D; Maletti S; Ferguson A; Cyrta J; Amstutz U; Garofoli A; Paradiso V; Tomlins SA; Hewer E; Genitsch V; Fleischmann A; Vassella E; Rushing EJ; Grobholz R; Fischer I; Jochum W; Cathomas G; Osunkoya AO; Bubendorf L; Moch H; Thalmann G; Ng CKY; Gillessen S; Piscuoglio S; Rubin MA
    Nat Commun; 2022 May; 13(1):2400. PubMed ID: 35504881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
    Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
    Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant invasion of the central nervous system: the hidden face of a poorly understood outcome of prostate cancer.
    de Oliveira Barros EG; Meireles Da Costa N; Palmero CY; Ribeiro Pinto LF; Nasciutti LE; Palumbo A
    World J Urol; 2018 Dec; 36(12):2009-2019. PubMed ID: 29980839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
    Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma.
    Yu J; Zhang H; Gu J; Lin S; Li J; Lu W; Wang Y; Zhu J
    BMC Cancer; 2004 Sep; 4():65. PubMed ID: 15367334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and genomic features of SPOP-mutant prostate cancer.
    Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
    Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
    Kang GH; Lee S; Lee HJ; Hwang KS
    J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
    Yegnasubramanian S; Kowalski J; Gonzalgo ML; Zahurak M; Piantadosi S; Walsh PC; Bova GS; De Marzo AM; Isaacs WB; Nelson WG
    Cancer Res; 2004 Mar; 64(6):1975-86. PubMed ID: 15026333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia.
    Gabriel AS; Lafta FM; Schwalbe EC; Nakjang S; Cockell SJ; Iliasova A; Enshaei A; Schwab C; Rand V; Clifford SC; Kinsey SE; Mitchell CD; Vora A; Harrison CJ; Moorman AV; Strathdee G
    Epigenetics; 2015; 10(8):717-26. PubMed ID: 26237075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotype-specific CpG island methylation events in a murine model of prostate cancer.
    Camoriano M; Kinney SR; Moser MT; Foster BA; Mohler JL; Trump DL; Karpf AR; Smiraglia DJ
    Cancer Res; 2008 Jun; 68(11):4173-82. PubMed ID: 18519676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm.
    Cho NY; Kim JH; Moon KC; Kang GH
    Virchows Arch; 2009 Jan; 454(1):17-23. PubMed ID: 19048291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.
    Kacprzyk LA; Laible M; Andrasiuk T; Brase JC; Börno ST; Fälth M; Kuner R; Lehrach H; Schweiger MR; Sültmann H
    PLoS One; 2013; 8(3):e59976. PubMed ID: 23555854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.